Mehta, Ashwani2025-05-092025-05-092024-03Mehta Ashwani . Managing dyslipidemia in solid organ transplant patients. Indian Heart Journal. 2024 Mar; 76(1): 93-950019-4832https://imsear.searo.who.int/handle/123456789/242776Solid organ transplant recipients face an increased risk of dyslipidemia, which contributes to cardiovascular complications. Commonly used drugs such as ciclosporin and tacrolimus can aggravate and cause dyslipidemia. Immunosuppressive drugs particularly ciclosporin and tacrolimus are also known to worsen dyslipidemia in transplant recipients. Mammalian target of rapamycin (mTOR) inhibitors like sirolimus and everolimus also alter lipid metabolism. Lifestyle and dietary modifications should be encouraged. Careful consideration of immuno- suppressant choices is also vital to control dyslipidemia. Statins are recommended as first-line agents for lipid- lowering therapy, with consideration for potential drug interactions. Other options, such as ezetimibe and nicotinic acid, may be considered as alternatives. The management of dyslipidemia in renal transplant patients mainly involves statin therapy, although the clinical effectiveness in this population is not well-documented. Lifestyle modifications, careful drug selection, and statin therapy are key components in managing dyslipide- mia in solid organ transplant patients.DyslipidemiaTransplant recipientsStatinsAscvdImmunosuppresive drugsAnd transplant vasculopathyJournal ArticleIndiaSir GangaRam Hospital, New Delhi, 110060, India